- Home
- ANTX vs EVAX Comparison
ANTX vs EVAX Comparison
Compare ANTX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANTX | EVAX |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2M | 33.4M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANTX | EVAX |
|---|---|---|
| Price | $1.16 | $3.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.00 | ★ $12.33 |
| AVG Volume (30 Days) | ★ 137.4K | 71.0K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,650,000.00 |
| Revenue This Year | N/A | $128.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 132.17 |
| 52 Week Low | $1.00 | $1.20 |
| 52 Week High | $1.55 | $12.15 |
Technical Indicators
Market Signals| Indicator | ANTX | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 28.33 |
| Support Level | $1.15 | $3.88 |
| Resistance Level | $1.28 | $4.85 |
| Average True Range (ATR) | 0.08 | 0.38 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 13.71 | 19.02 |
Price Performance
Historical ComparisonAbout ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.